RVX-208 - BET Bromodomain Inhibitor. CAS# 1044870-39-4 60428 Smiles: CC(C1CCN(CC1)S(=O)(=O)CC)N1C2=CC=CC=C2C(C(=O)NCC2=C(C=C(C)NC2=O)OC)=C1C

Smiles: CC(C1CCN(CC1)S(=O)(=O)CC)N1C2=CC=CC=C2C(C(=O)NCC2=C(C=C(C)NC2=O)OC)=C1C

including murine and rat mechanistic breast cancer models driven by MMTV–Wnt1 and a human head and neck squamouscell carcinoma model (HN30)

induces apoptosis in NSCLC cells

KDM5-C70 was used at 1-10 µM in vitro and cellular assays

(2009) Nat Biotechnol

RVX-208 - BET Bromodomain Inhibitor. CAS# 1044870-39-4 60428 Smiles: CC(C1CCN(CC1)S(=O)(=O)CC)N1C2=CC=CC=C2C(C(=O)NCC2=C(C=C(C)NC2=O)OC)=C1CRVX 208, CAS No. 1044870 39 4, also known as Apabetalone, is a potent inhibitor of BET bromodomains. RVX 208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT). RVX 208 increases the production of ApoA I in hepatocytes in vitro, and in vivo in monkeys and humans, which results in increased HDL C, but the molecular target was not previously reported. RVX 208 may be a promising new approach to the treatment of